The statements Toronto Raptors contained in this release

The statements surmises toronto raptors contained in air canada centre raptors informs this release that are not historical facts areforward-looking statements that represent management`s beliefs and assumptionsbased on currently available information.Forward-looking statements can beidentified by the use of words such as "believes," "may," "will," "looks,""should," "could," "anticipates," "expects," or comparable terminology or bydiscussions of strategies or trends.Although the Company believes that theexpectations reflected in such forward-looking statements are reasonable, itcannot give any assurances that these expectations will prove to be correct.Such statements by their nature involve substantial risks and uncertainties thatcould significantly affect expected results.Actual future results could differmaterially from those described in such forward-looking statements, and theCompany does not intend to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise.Among thefactors that could cause actual results to differ materially are the risks anduncertainties discussed in this release and those described from time to time inother filings with the Securities and Exchange Commission which include, but arenot limited to, competition; the possibility of interruption of businessactivities due to equipment problems, accidents, strikes, weather or otherfactors; product development risk; changes in corn and other raw material pricesand availability; expectations regarding the construction cost of theethanolfacility and the timing of ethanol production; changes in general economicconditions or developments with respect to specific industries or customersaffecting demand for the Company`s products, including unfavorable shifts inproduct mix; unanticipated costs, expenses or third party claims; the risk thatresults may be affected by construction delays, cost overruns, technicaldifficulties, nonperformance by contractors or changes in capital improvementproject requirements or specifications; interest rate, chemical and energy costvolatility; foreign currency exchange rate fluctuations; changes in assumptionsused for determining employee benefit expense and obligations; other unforeseendevelopments in the industries in which Penford operates; and other factorsdescribed in the "Risk Factors" section in reportsfiled by the Company with theSecuritiesand Exchange Commission. Penford CorporationThree months ended Financial Highlights November 30, (In thousands except per share data)20082007 (unaudited)Consolidated Results Sales$80,690 $94,861Net income (loss)$(369)$3,162 Earnings (loss) per share, diluted $(0.03) $0.33Results by Segment Industrial Ingredients: Sales$41,841 $49,209Gross margin0.3%17.4% Operating income1,799 5,696 Food Ingredients - North America: Sales$17,742 $16,076Gross margin29.7% 28.3% Operating income3,398 2,652 Australia/New Zealand:Sales$21,360 $29,944Gross margin(0 Raptors tickets - nba .1)%10.5% Operating loss(1,533) (75)November 30,August 31,20082008(unaudited) Current assets$101,128 $95,737Property, plant and equipment, net 157,174169,932 Other assets 34,842 44,712Total assets 293,144310,381 Current liabilities57,632 58,322Long-term debt 64,424 59,860Other liabilities30,703 31,837Shareholders` equity 140,385160,362 Total liabilities and equity$293,144 $310,381 Penford CorporationThree months endedConsolidated Statements of Income (unaudited)November 30,(In thousands except share and per share data)20082007Sales$80,690 $94,861 Cost of sales 75,30278,608Gross margin5,388 16,253 Operating expenses7,267 7,240 Research and development expenses 1,519 2,022 Flood costs, net of insurance proceeds(4,234) - Restructure costs - 1,235Income from operations836 5,756Non-operating income (loss), net(210) 464 Interest expense1,492 1,266Income (loss) before income taxes (866) 4,954Income tax expense (benefit)(497) 1,792Net income (loss)$(369)$3,162Weighted average common shares and equivalents outstanding, diluted 11,155,2569,548,803Earnings (loss) per share, diluted $(0.03 )$0.33 Dividends declared per common share$0.06 $0.06 Penford CorporationSteven O. Cordier, 303-649-1900Senior Vice President and Copyright Business Wire 2009.  The best hockey player in the world returned to the ice last night after missing 6 games with a shoulder injury and gave the Capitals their 1st of 4 goals on the night.Ovie’s 15th goal of the season tied the score at 1-1, after Marian Gaborik gave the Rangers the early 1-0 lead, scoring just 1:16 into the game. Ovechkin’s goal came on the Caps power play from the point, a booming slap shot screened perfectly by Chris Clark and Brooks Laich. Despite out shooting the Rangers 15-5 in the first period, the period ended in a 1-1 tie.The lone second period goal came on the Caps power play, a rebound put in by Brooks Laich, his 5th power play goal of the season, leading the Capitals special teams.  Mike Green and Chris Clark had the assists.  The second period was a pure defensive period as both teams put up a combined 12 shots 0n goal (6-6).Gaborik scored the equalizer and his 2nd goal of the night a little over the 8 minute mark in the third period, a shot to the side of the net, up over Semyon Varlamov’s right shoulder.  That goal was number 15 for Gaborik, keeping him tied with Alex Ovechkin for the NHL lead, despite Oveckin’s 6 game layoff.  A little over the 15 minute mark, a stitched up Matt Bradley, bloodied from a second period fight, took a pseudo-breakway and owned Ranger’s goalie Henrik Lundqvist to give the Caps a 3-2 lead they would not relinquish.

  It was Bradley’s 4th goal of the season, putting him 1 goal away from his total of 5 goals all of last year.  The final goal came on a flick away by Brian Pothier into the empty Rangers net to seal the 4-2 win over the Rangers.Varlamov saved 18 of 20 shots to improve to an impressive 8-1 on the season.Read it all at toronto star raptors . SANTA CLARA, Calif.--(Business Wire)--Global ophthalmic company OptiMedica Corp has appointed medical device industryveteran Stephen P Hanlon as vice president of research and development basketball . In thisnewly created position, Hanlon will be responsible for driving new technologyand product innovation for the company bulls raptors . "Steve`s deep medical technology experience and proven track record ofinnovation make him the perfect choice to lead OptiMedica`s substantial researchand development efforts as we develop new additions to our growing portfolio ofproducts," said Mark J Forchette, president and chief executive officer buy raptor tickets raptors.com . "He isjoining a very seasoned management team that has demonstrated remarkable successdesigning, developing and commercializing PASCAL technology that has alreadybenefited hundreds of thousands of patients around the world. We look forward toworking with Steve to accelerate the development of new technologies andproducts that meet the highest standards of excellence in the ophthalmicindustry." Hanlon brings to OptiMedica more than 25 years of leadership experience inmedical technology research and development, with areas of focus includingstereotactic radiosurgery, image-guided surgery, implantable devices,electrosurgery and dialysis products. He was previously vice president ofresearch and development for Boston Scientific`s Neurovascular Division, wherehe oversaw a 100-person multi-disciplinary department and numerous successfulproduct launches.

Prior to Boston Scientific, he served as vice president ofoperations for Photoelectron Corp . as well as vice president and general managerof the Radionics division of Tyco Healthcare (now Covidien) buy raptors tickets . "OptiMedica represents the exciting convergence of sophisticated technology witha clear need for better treatment options for a large and growing patientpopulation," said Hanlon buy toronto raptor tickets . "I look forward to bringing my experience withbest-in-class medical device companies to bear for OptiMedica in thisfast-moving, high-tech market." About OptiMedicaBased in Santa Clara, Calif., OptiMedica Corp Raptors tickets . is a global ophthalmic companydedicated to advancing the practice of ophthalmology for the benefit ofphysicians and their patients. The company holds the exclusive license to thePASCAL Photocoagulator technology, which was originally developed at StanfordUniversity. OptiMedica is funded by Kleiner Perkins Caufield & Byers, AlloyVentures and DAG Ventures For more information, please visit

Newmont expects 2009 costs applicable to gold sales of $400to $440 per ounce. ) This week's Grand Prix in Monaco has come at a great time, giving everyone a short weekend break from the politics and in-fighting that has marred the sport so far this season. With practice sessions on a Thursday as always in Monaco, the teams have an extra day to prepare for the race and make adjustments to their cars after practice Toronto Raptors - wikipedia . The DVDs and photo cards will beelegantly presented in a deluxe tri-fold rigid case that is exclusive toBorders Toronto Raptors tickets Toronto Raptors . It is a decision that we believe Benjamin Graham, one of theFathers of Value Investing, would have initiated had he been confronted withthese circumstances nba.com - raptors .

Can the tandem of Josh Howard and Dirk Nowitzkiout-duel Carmelo Anthony and Nene?The Nuggets have been my favorite team to watch all season, and the weaponry they bring to the table will scare the crap out of Rambo.With a healthy Nene Hilario and Melo Buckets, Dallas has its' hands full in this series. For more information, please visit the company's web site at http://[1] Classen, Lambert, "Colorectal Cancer Screening in Europe, a Survey ofthe International Digestive Disease Alliance between November 2004and March, 2007"[2] Boyle, P Toronto Raptors tickets - nba ., Ferlay, J., "Cancer incidence and mortality in Europe. From the top of the key to the basket, there was only green paint in the lane until Rondo showed up at the last moment.There were two things that had the Bulls livid. This is a fantastic pick for the Cardinals, as they were set to head into next year with Tim Hightower as the feature back.Worst value: Darrius Heyward-Bey, WR, Maryland to the Raiders, No Raptors . Speakers will discuss new business models, international businessopportunities, the likely impact of the economic recession and other topicsfor game industry professionals.Highlighted speakers include: John O'Neill, Spark Plug Games; AlexanderMacris, Themis Media; Juan Benito, Destineer StudiosIn addition to lectures and panels, TGC will feature an Expo, Career Loungeand Game Development University, a student-oriented exhibition to helpaspiring game developers tap into educational resources and make connectionswith industry leaders."The Triangle Game Conference is the first of its kind for our region, andEpic Games is proud to support it," said Dr Michael Capps, president of EpicGames.